PharmaFocus Today – Page 48 – media

Wegovy Linked To Lower Heart Risks Than Similar Drugs, Study Shows

WEDNESDAY, Sept. 3, 2025 (HealthDay News) — The weight-loss drug Wegovy may lower the risk of heart attack, stroke or death more than similar medications, according to new research from its maker, Novo Nordisk. In a study of more than 21,000 patients with obesity and heart disease but no diabetes, those taking Wegovy — which contains the active ingredient semaglutide — saw a 57% greater reduction in heart-related risks compared to people taking tirzepatide, the ingredient in Eli Lilly’s weight-loss drugs Mounjaro and Zepbound. The findings were presented at a medical conference and have not yet been peer-reviewed or published. As such, they should be regarded as preliminary. “This data confirms that semaglutide stands apart as the only available GLP-1-based medication with proven cardiovascular benefits for people living with obesity and cardiovascular disease, without diabetes,” Ludovic Helfgott, Novo Nordisk’s head of product and portfolio strategy, said in a news release. ...
- Source: drugdu
- 109
- September 4, 2025
OPM plans to acquire 100% of Pengli Biopharmaceuticals and lowers its private placement to 362 million yuan.

An announcement was issued on September 4, stating that the company plans to purchase 100% of the equity of Pengli Biotechnology (Shanghai) Co., Ltd. (hereinafter referred to as “Pengli Biotechnology” or “the target company”) through the issuance of shares and payment of cash, and to issue shares to no more than 35 specific investors to raise matching funds. The company previously received an audit inquiry letter from the Shanghai Stock Exchange and has completed its response to the relevant questions. The company’s independent financial advisor, accounting firm, law firm, and appraisal agency have reviewed the relevant matters in the audit inquiry letter and issued clear opinions. They have also revised the relevant documents and materials previously released by the company. The company has reviewed and self-examined the entire text of the “Restructuring Report” (revised draft), and has made minor additions to the text, which have no impact on the transaction ...
- Source: drugdu
- 144
- September 4, 2025
Fukang Pharmaceuticals files for Hong Kong IPO

Recently, Fukang Pharmaceutical officially submitted an application for listing on the main board of the Hong Kong Stock Exchange, marking a key step towards the capital market. Founded in 2015, Fukang Pharmaceuticals is a clinical-stage, global, and China-based company dedicated to developing innovative medicines for oncology, viral diseases, and aging-related diseases. Fukang’s core team primarily hails from leading domestic and international pharmaceutical companies such as Novartis and Huahai Pharmaceuticals, and the company collaborates with renowned research institutes both domestically and internationally, including the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. According to its prospectus, Fukang Pharmaceutical has established a diversified product portfolio consisting of one commercialized product, two core products, two key products, and 12 other drug candidates under development. Of these 16 drug candidates, five are in Phase I/II clinical development, seven are in preclinical development, and four are generic drug candidates. Its pipeline focuses primarily on ...
- Source: drugdu
- 138
- September 4, 2025
Sales of herpes zoster vaccines suffered a setback, with Beike Bio turning from profit to loss in the first half of this year.

Beike BioRecently, the company disclosed its 2025 semi-annual report. During the reporting period, the company achieved revenue of only RMB 285 million, a year-on-year decline of 53.93%; the net profit attributable to the parent company was RMB -73.5734 million, a sharp year-on-year decline of 153.47%. The main reason affecting the performance was that the sales of herpes zoster vaccine fell short of expectations. Since 2024, Beike Bio’s performance has declined sharply, and in the first half of this year, it turned from profit to loss. With the sales of core products falling short of expectations, the nasal spray flu vaccineThe live attenuated vaccine (liquid preparation) was approved for marketing in the first half of this year. With the advancement of the commercialization of the new product, can it boost Beike Bio’s performance in the second half of the year? Core product sales suffered setbacks Beike Bio’s revenue mainly depends on ...
- Source: drugdu
- 364
- September 4, 2025
Zhonghui Bio’s quadrivalent influenza virus subunit vaccine marketing application approved

On September 3, Zhonghui Bio announced that the National Medical Products Administration has approved the company’s quadrivalent influenza vaccine　　for people aged 6-35 months.The new drug application for the influenza virus subunit vaccine was filed. The announcement shows that this vaccine has become the first and only full-dose quadrivalent influenza virus subunit vaccine approved for marketing in China. https://finance.eastmoney.com/a/202509033503778045.html
- Source: drugdu
- 242
- September 4, 2025
Revascularization strategy fails to show noninferiority in STEMI patients

Noninferiority was not demonstrated between immediate and staged complete revascularisation in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease undergoing percutaneous coronary intervention (PCI), according to late-breaking research presented in a Hot Line session today at ESC Congress 20251. Multivessel coronary artery disease – when at least two coronary arteries are blocked – affects almost half of patients who have STEMI, a type of heart attack. ESC Guidelines recommend complete revascularisation with PCI in patients with STEMI and multivessel disease, involving treating the blocked artery that caused the heart attack (culprit lesion) plus other affected vessels (non-culprit lesions).2 Explaining the aim of the OPTION-STEMI trial, its Principal Investigator, Professor Youngkeun Ahn from Chonnam National University Hospital, Gwangju, South Korea, stated, “We compared immediate complete revascularisation with PCI for the culprit and non-culprit lesions during the same procedure with staged complete revascularisation, where PCI for non-culprit lesions took place ...
- Source: drugdu
- 139
- September 2, 2025
Brain pulsations driving glymphatic function differ in narcolepsy patients and healthy individuals

A hormone produced by the brain, orexin, may play a central role in the functioning of the brain’s glymphatic system, which clears waste, according to a new study from the University of Oulu. Published in the high-profile journal PNAS, the study examined how the pulsations driving the brain’s glymphatic clearance differ in people with narcolepsy type 1 compared with healthy individuals. For the first time, the research directly compared the brain pulsations of narcolepsy patients with those of healthy individuals during sleep. The study included 23 participants with narcolepsy type 1 and a group of healthy controls. Brain clearance involves three types of pulsation: cardiovascular pulsations generated by the heartbeat in the arteries, respiratory pulsations in the veins and cerebrospinal fluid spaces, and slow vasomotor waves in the walls of blood vessels. These pulsations, and the resulting brain clearance, are known to increase during sleep. Previous research has shown that ...
- Source: drugdu
- 121
- September 2, 2025
Alzheimer’s disease drug subcutaneous injection approved in the US

On August 29th local time, Japan’s Eisai Co., Ltd. and the US Biogen Inc. announced that the US FDA (U.S. Food and Drug Administration) has approved the weekly maintenance dose of lencanelumab subcutaneous automatic injection (SC-AI) for the treatment of early Alzheimer’s disease (AD). Comment: As of now, there are limited AD treatment drugs approved worldwide. This approval makes Lencaneluzumab the first AD treatment drug that can be administered subcutaneously at home using an automatic injector. The entire injection process takes an average of only 15 seconds, which further consolidates the company’s market position in this field. https://finance.eastmoney.com/a/202509013500390220.html
- Source: drugdu
- 117
- September 2, 2025
The new king of the multi-billion myeloma market is here

In the multi-billion dollar global myeloma market, BCMA/CD3 bispecific antibodies are becoming a powerful weapon reshaping the treatment landscape. Currently, the market is dominated by Johnson & Johnson, Pfizer, and Regeneron, with competition escalating. Digging for Gold in the Billion-Dollar Myeloma Market Multiple myeloma, a common hematologic malignancy, is experiencing an expanding global market for treatment. The market reached $28.3 billion in 2024 and is projected to continue growing at an average annual rate of 6.6%. Industry forecasts predict the market will exceed $52.1 billion by 2032. The global multiple myeloma market is currently characterized by a competitive landscape characterized by the simultaneous advancement of traditional drugs, biologics, and cell therapies. Forecast sales of key multiple myeloma therapeutics in major markets from 2024 to 2033 Image source: Nature reviews. Drug discovery, 24(4), 244–245. Among core therapeutic drugs, immunomodulators (IMiDs) still hold a significant position. Lenalidomide, a second-generation drug, continues to ...
- Source: drugdu
- 177
- September 2, 2025
Another breakthrough in overseas expansion! Henlius receives FDA approval for two osteoporosis treatment drugs

On September 1, Henlius Biopharmaceuticals (02696) announced that it had recently received approval from the U.S. Food and Drug Administration (FDA) for the development of two HLX14 (denosumab)-related products, BILDYOS® and BILPREVDA®.The license application was approved. These two products are used to treat osteoporosis and prevent bone-related events in specific populations, respectively. Specific indications include the treatment of osteoporosis in postmenopausal women and men, glucocorticoid-induced osteoporosis, and bone metastases in patients with multiple myeloma. https://finance.eastmoney.com/a/202509023502086989.html
- Source: drugdu
- 107
- September 2, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.